Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19

Saved in:

Bibliographic Details
Main Authors:	Han Yan, Shanbiao Hu, Hedong Zhang, Yangang Zhou, Rao Fu, Ping Xu, Hualin Cai, Xi Li, Gongbin Lan
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124500/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tacrolimus Toxicity in Two Renal Transplant Recipients Treated With Nirmatrelvir/Ritonavir: A Case Series
by: Meaghan Coyne, et al.
Published: (2023-03-01)

A comparative study of clinical outcomes and risk factors of tuberculosis in kidney transplant recipients from deceased donors
by: Hedong Zhang, et al.
Published: (2025-03-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
by: Ping Xu, et al.
Published: (2024-12-01)

Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients
by: Orhan Efe, et al.
Published: (2024-12-01)

Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period
by: A. V. Shabunin, et al.
Published: (2023-04-01)

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
by: Franco Wing Tak Cheng, et al.
Published: (2024-05-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
by: Rani Sawtell, et al.
Published: (2025-12-01)

Patiromer Does Not Alter Tacrolimus Pharmacokinetics in Kidney Transplant Recipients When Administered Three Hours Post–Tacrolimus
by: Ole Martin Drevland, MSc, et al.
Published: (2024-12-01)

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01)

Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
by: Christopher G. Rowan, et al.
Published: (2024-12-01)

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01)

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
by: Andrea Di Lenarda, et al.
Published: (2024-08-01)

Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients
by: Anna Tsironi, et al.
Published: (2025-03-01)

WCN24-1499 TACROLIMUS-INDUCED HYPOMAGNESEMIA IN A KIDNEY TRANSPLANT RECIPIENT
by: Wanprapit Noree, et al.
Published: (2024-04-01)

The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients
by: Napatsorn Kraivisitkul, et al.
Published: (2025-01-01)

Assessing drug-drug interactions of Tacrolimus with Fluconazole and/or Verapamil and developing the predictive model for Tacrolimus concentrations in kidney transplant recipients
by: Mingkwan Na Takuathung, et al.
Published: (2025-06-01)

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
by: Satriyo Dwi Suryantoro, et al.
Published: (2021-09-01)

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions
by: Zhiqing Fu, et al.
Published: (2025-03-01)

The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease
by: Marcin Wełnicki, et al.
Published: (2025-05-01)

Intrapatient tacrolimus variability is associated with medical nonadherence among pediatric kidney transplant recipients
by: Tara B. Gavcovich, et al.
Published: (2025-03-01)

The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience
by: Huanxi Zhang, et al.
Published: (2024-12-01)

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection
by: Yun Han, et al.
Published: (2025-05-01)

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01)

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01)

Effect of tacrolimus formulation on neurocognition in older kidney transplant recipients: A randomized controlled trial
by: Hadia Lala Gul, et al.
Published: (2025-09-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19
by: Aisling R. Caffrey, et al.
Published: (2025-04-01)

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19
by: Carolina Moreno, et al.
Published: (2025-07-01)

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
by: Chuntao Li, et al.
Published: (2025-07-01)

Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients
by: Svea Nolte, et al.
Published: (2025-04-01)

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity
by: Shruti Gupta, et al.
Published: (2018-01-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study
by: Jingxia Chen, et al.
Published: (2025-04-01)

Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
by: Guang‐Bin Chen, et al.
Published: (2024-06-01)

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01)